Overview Safety, Tolerability, and Preliminary Efficacy of Soquelitinib in Participants With Moderate to Severe AD Status: RECRUITING Trial end date: 2025-11-01 Target enrollment: Participant gender: Summary Safety, tolerability, and preliminary efficacy of soquelitinib in participants with moderate to severe ADPhase: PHASE1 Details Lead Sponsor: Corvus Pharmaceuticals, Inc.